One of the primary reasons drug-eluting devices have garnered attention is their capacity to precisely deliver therapeutic agents to specic anatomical sites within the body [14]. This precision is of paramount importance in conditions where the pathological process is conned to a specic tissue or organ, such as in the case of cardiovascular stents delivering antiproliferative agents to prevent restenosis [15]. These devices optimize drug concentrations at the target by delivering therapeutic agents directly to the site of action, maximizing treatment effectiveness. This tar­geted delivery not only improves the overall therapeutic outcomes but also allows for the use of lower drug doses, mitigating the risk of systemic toxicity and adverse effects commonly associated with higher systemic drug concentrations [16]. Furthermore, the capacity of drug-eluting devices to minimize systemic side effects contributes to an improved safety prole in comparison to traditional systemic drug administration. This is particularly signicant in the context of chronic diseases or conditions requiring prolonged treatment, where systemic exposure to drugs may lead to complications. Drug-eluting devices thus offer a more patient-centric approach by reducing the likelihood of adverse reactions and enhancing overall treatment adherence [17, 18]. The precise and targeted delivery facilitated by drug­eluting devices has profound implications across various medical domains, includ­ing cardiology, oncology, neurology, and orthopedics. As a result, the biomedical community is increasingly recognizing the potential of these devices to revolution­ize therapeutic strategies, providing more effective and patient-friendly solutions. Ongoing research and technological advancements in this eld continue to rene drug-eluting devices, pushing the boundaries of what can be achieved in terms of precision, selectivity, and therapeutic impact [16, 19].